Answers are grounded in this paper and cite their sources.
Case report reveals successful resolution of persistent monoarthritis via H. pylori treatment, implying need for screening.
Helicobacter pylori (H. pylori) is a prevalent gastric pathogen increasingly recognized as a potential trigger for extra-gastric inflammatory conditions. Despite this, its association with reactive arthritis (ReA) remains under-reported and is often overlooked in the differential diagnosis of seronegative arthritis. A 19-year-old female presented with a five-month history of persistent inflammatory monoarthritis of the left knee. The condition was refractory to non-steroidal anti-inflammatory drugs (NSAIDs), intra-articular corticosteroid injections, and conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), including methotrexate and sulfasalazine. Clinical investigations revealed an inflammatory, aseptic synovial effusion, while serological markers - including antinuclear antibodies (ANA), rheumatoid factor (RF), and anticyclic citrullinated peptide (anti-CCP) - and human leukocyte antigen B27 (HLA-B27) were negative. A concurrent evaluation for dyspepsia identified an active H. pylori infection via a urea breath test. Following the discontinuation of all immunosuppressive therapy and the administration of a 10-day triple eradication regimen, the patient achieved complete and sustained clinical and biochemical remission, which was maintained at a three-month follow-up. This case underscores the importance of considering H. pylori as a causative agent in cases of unexplained, treatment-refractory monoarthritis. Systematic screening for H. pylori may identify a reversible infectious trigger, potentially preventing unnecessary long-term immunosuppression and biological therapy in young patients.
No takes yet. Share an insight, caveat, or question.
Yarden Assabag (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: